Skip to main content
. 2012 Sep 19;23(4):235–241. doi: 10.3802/jgo.2012.23.4.235

Fig. 1.

Fig. 1

Progression-free (A) and overall survival (B) according to the type of concurrent chemoradiation therapy (CCRT) in 255 locally advanced cervical cancer patients. The 5-yr progression-free survival and overall survival of patients in the group given weekly CCRT versus monthly CCRT are 74.6% vs. 64.3% and 78% vs. 73%, respectively. FP, 5-fluorouracil plus cisplatin.